Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENALUT: 177Lu-PSMA-617 in Metastatic Clear Cell Renal Cell Carcinoma
NCT06783348Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in clear cell renal cell carcinoma (ccRCC), sponsored by European Organisation for Research and Treatment of Cancer. Started Apr 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06783348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783348.